March 14, 2017
March 9, 2017
Watch our most recent webinar: New Diagnostics Guiding Oncology Treatment Decisions
Webinar Information: The Canadian Cancer Survivor Network was pleased to offer another webinar on precision medicine and diagnostic services, welcoming oncology and pathology centre expertise along with policy experts to...
Read More
March 2, 2017
Register for our upcoming webinar: New Diagnostics Guiding Oncology Treatment Decisions
Webinar Information: The Canadian Cancer Survivor Network is pleased to offer another webinar on precision medicine and diagnostic services, welcoming oncology and pathology centre expertise along with policy experts to...
Read More
March 1, 2017
Watch our most recent webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar Information: The upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money...
Read More
February 27, 2017
BC Pharmacare approves innohep
Effective February 14, 2017, BC Pharmacare has approved innohep for the additional indication of CAT for up to 6 months. For more information, please click here.
Read More
February 27, 2017
Making Canada Better, Innovative Medicines Canada Event Report
The following event report is the summary of Making Canada Better conference that was held this past November by Innovative Medicines Canada. Please click here to view the report.
Read More
February 27, 2017
Webinar – Healthcare in the Federal Budget and How It May Affect Patients
Webinar Information: The upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money...
Read More
February 21, 2017
CCSN Survey on Rituxan (Rituximab)
The purpose of this survey is to provide us with the needed insights and perspectives about the use of Rituxan (Rituximab) for the treatment of patients with Philadelphia chromosome-negative, CD20 antigen positive, B-cell precursor...
Read More
February 16, 2017
BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells
Development of promising engineered T cell therapy part of $11 million investment in 16 collaborative research projects in novel therapies to cure cancer OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET - BioCanRx, and its partners, today...
Read More
February 14, 2017
National Agreement Reached between Pan-Canadian Pharmaceutical Alliance and Bristol-Myers Squibb for Immuno-Oncology Treatment OPDIVO® (nivolumab)
Decisions on public reimbursement now in hands of provincial and territorial jurisdictions MONTREAL, Feb. 10, 2017 /CNW/ - Bristol-Myers Squibb Canada Co. today announced that the company has reached an...
Read More